IPP Bureau
Innovent announces 2nd BTD by NMPA for Olverembatinib for treatment of patients with SDH-deficient GIST
By IPP Bureau - June 03, 2023
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Sure Med Compliance partners with Galt Phranchise Systems to support better outcomes in pain patients
By IPP Bureau - June 03, 2023
Strategies aimed at solving the current overdose epidemic must go beyond the identification of risk
Novartis receives European approval for Cosentyx
By IPP Bureau - June 03, 2023
European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
3M to invest nearly $150 million on expanding biopharma filtration capabilities
By IPP Bureau - June 03, 2023
The investment will include facility and equipment improvements and the addition of 60 full-time positions in 3M manufacturing facilities in Europe.
AstraZeneca receives CDSCO approval for Tremelimumab combination in India
By IPP Bureau - June 02, 2023
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Evonik launches next-generation peptide for biopharma applications
By IPP Bureau - June 02, 2023
One thousand times more soluble than L-cystine at neutral pH
Philips and Masimo introduce advanced monitoring capabilities to Philips high acuity patient monitors
By IPP Bureau - June 02, 2023
The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment
Pfizer’s phase 3 studies of novel antibiotic combination offer new hope for patients with multidrug-resistant infections and treatment options
By IPP Bureau - June 02, 2023
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Merck partners with California-based research group to study catalysis innovation through machine learning
By IPP Bureau - June 02, 2023
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy
By IPP Bureau - June 02, 2023
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Lonza acquires biotech firm Synaffix
By IPP Bureau - June 02, 2023
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Laurus Labs to increase stake in ImmunoACT to 33.86%
By IPP Bureau - June 01, 2023
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
USFDA inspects contract manufacturing facility of Jubilant Pharmova at Montreal Canada
By IPP Bureau - June 01, 2023
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
Lupin receives USFDA approval from Obeticholic Acid Tablets
By IPP Bureau - June 01, 2023
Obeticholic Acid Tablets had estimated annual sales of US$ 262 million in the U.S. (IQVIA MAT Mar 2023).
Honeywell refurbishes PHCs in rural India across three states
By IPP Bureau - June 01, 2023
The project is part of a three-year-long partnership between Honeywell and Americares to strengthen the health infrastructure in rural Maharashtra, Uttarakhand and Haryana
